相关实验视频

Updated: May 21, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

针对CD24的CAR-T细胞通过激活内源性瘤免疫反应来调解长期的抗瘤疗效

Yong Huang¹, Xiao Yang¹, Jing Li²

¹Sichuan University, Chengdu, China.

Molecular cancer therapeutics

|March 19, 2025

概括

针对CD24免疫检查点的化学抗原受体T细胞 (CAR-T) 治疗显示出对固体瘤有强大的抗瘤作用. 这种方法增强了内源性免疫反应,导致长期瘤回归,并在临床前模型中抵抗瘤再发作.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

卡特-T疗法在B细胞恶性瘤中取得了成功,但由于免疫抑制性瘤微环境,在固体瘤中面临挑战.
瘤微环境损害了CAR-T细胞杀死能力,扩张和持久性,降低了治疗疗效.
引起内源性免疫反应可以增强和维持CAR-T疗法的抗瘤作用.

研究的目的:

研究CAR-T细胞向CD24的疗效,CD24是一种瘤生物标志物和先天免疫检查点.
评估针对CD24的CAR-T细胞在克服固体瘤相关免疫抑制方面的潜力.
为了确定CD24CAR-T疗法是否可以引起持久的抗瘤免疫力.

主要方法:

针对CD24的CAR-T细胞的发展 (CD24 CAR-T).
在体外细胞毒性测定对CD24阳性癌细胞.
在免疫缺陷和免疫能力的小鼠模型中的体内研究.
进行了瘤生长抑制和再挑战实验.
分析内源性免疫反应,包括IFN-γ释放和抗体产生.

主要成果:

在实验室中,CD24 CAR-T细胞对CD24阳性癌细胞表现出强大的细胞毒性.
在免疫缺陷小鼠中观察到显著抑制瘤生长.
强大的抗瘤活性和没有观察到免疫能力的小鼠的副作用.
用CD24 CAR-T细胞治疗的小鼠表现出对CD24阳性和阴性瘤复发的抵抗力.
检测到激活的内源性免疫反应,由IFN-γ释放和瘤反应性抗体证明.

结论:

在临床前的固体瘤模型中,CD24 CAR-T细胞表现出优越的抗瘤疗效.
用CAR-T细胞准CD24免疫检查点可以激活内源性抗瘤免疫力.
这一策略有望改善固体瘤中CAR-T治疗结果.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...